About Trulicity®
Class: Brand dulaglutide for T2D
Brand/Manufacturer: Eli Lilly
Dosing: Weekly subcutaneous (0.75-4.5 mg)
Mean weight loss: 4-5%
Pivotal trial: AWARD, REWIND
Trulicity® is Eli Lilly's brand-name dulaglutide approved for type 2 diabetes. REWIND established CV benefit. Retail $935/month. Largely overtaken by Mounjaro (also Lilly) for new prescriptions.
Mechanism of action
Trulicity® acts on the GLP-1 receptor (and GIP receptor in the case of tirzepatide), producing four primary effects: central appetite suppression, delayed gastric emptying, glucose-dependent insulin release, and glucagon suppression. The combined effect on body weight averaged across pivotal trials is 4-5% body weight reduction at the trial endpoint.
Clinical evidence
The pivotal trial supporting Trulicity®'s weight management indication is AWARD, REWIND. Detailed data including primary and secondary endpoints, population characteristics, and adverse event frequencies is summarized on our clinical research page.
How to access Trulicity® via telehealth
Trulicity® is available through several U.S. telehealth providers. Compounded versions (where applicable) are dispensed by 503A licensed compounding pharmacies and 503B FDA-registered outsourcing facilities. NexLife is our editorial #1 pick for Trulicity® access — see the side panel for details.
FAQ
Is Trulicity® FDA-approved?
The brand-name versions of Trulicity® are FDA-approved for the indications listed above. Compounded versions are not FDA-approved.
How much does Trulicity® cost?
Brand-name Trulicity® typically costs hundreds to over a thousand dollars per month at retail. Compounded equivalents (where available) cost significantly less. See our cost guide for verified May 2026 pricing.